[新的美国医学杂志文章：纳武单抗用于一线化疗后的晚期食管鳞状细胞癌] - Suppr

Suppr

超能文献

[New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].

作者信息

Reich Mathilde, Coutzac Clelia

机构信息

Institut Curie, hôpital René-Huguenin, département d'oncologie médical, 35, rue Dailly, 92210 Saint-Cloud, France.

Centre Léon Bernard, département d'oncologie médicale, 28, rue Laënnec, 69008 Lyon, France.

出版信息

Bull Cancer. 2021 Mar;108(3):228-229. doi: 10.1016/j.bulcan.2020.12.005. Epub 2021 Jan 30.

DOI:10.1016/j.bulcan.2020.12.005

PMID:33531154

Abstract

摘要

相似文献

[New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].

Bull Cancer. 2021 Mar;108(3):228-229. doi: 10.1016/j.bulcan.2020.12.005. Epub 2021 Jan 30.

[New AMM: Nivolumab as an adjuvant for oesophageal and gastroesophageal junction cancer].

Bull Cancer. 2022 Apr;109(4):389-390. doi: 10.1016/j.bulcan.2021.11.018. Epub 2022 Feb 11.

Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma.

Future Oncol. 2020 Jun;16(17):1189-1198. doi: 10.2217/fon-2019-0821. Epub 2020 May 14.

[New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)].

Bull Cancer. 2022 Feb;109(2):109-110. doi: 10.1016/j.bulcan.2021.11.012. Epub 2022 Jan 4.

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30.

[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10].

Bull Cancer. 2022 Feb;109(2):111-113. doi: 10.1016/j.bulcan.2021.09.021. Epub 2022 Jan 5.

[Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report].

Rinsho Shinkeigaku. 2020 Nov 27;60(11):768-772. doi: 10.5692/clinicalneurol.cn-001443. Epub 2020 Oct 27.

A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.

Eur J Cancer. 2020 Nov;139:169-172. doi: 10.1016/j.ejca.2020.08.005. Epub 2020 Sep 29.

[Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].

Rev Med Interne. 2020 Apr;41(4):284-288. doi: 10.1016/j.revmed.2019.12.023. Epub 2020 Jan 23.

Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinoma.

Future Oncol. 2024;20(28):2097-2107. doi: 10.1080/14796694.2024.2345043. Epub 2024 May 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].

作者信息

Reich Mathilde, Coutzac Clelia

机构信息

Institut Curie, hôpital René-Huguenin, département d'oncologie médical, 35, rue Dailly, 92210 Saint-Cloud, France.

Centre Léon Bernard, département d'oncologie médicale, 28, rue Laënnec, 69008 Lyon, France.

出版信息

Bull Cancer. 2021 Mar;108(3):228-229. doi: 10.1016/j.bulcan.2020.12.005. Epub 2021 Jan 30.

DOI:10.1016/j.bulcan.2020.12.005

PMID:33531154

Abstract

摘要

相似文献

[New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].

Bull Cancer. 2021 Mar;108(3):228-229. doi: 10.1016/j.bulcan.2020.12.005. Epub 2021 Jan 30.

[New AMM: Nivolumab as an adjuvant for oesophageal and gastroesophageal junction cancer].

Bull Cancer. 2022 Apr;109(4):389-390. doi: 10.1016/j.bulcan.2021.11.018. Epub 2022 Feb 11.

Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma.

Future Oncol. 2020 Jun;16(17):1189-1198. doi: 10.2217/fon-2019-0821. Epub 2020 May 14.

[New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)].

Bull Cancer. 2022 Feb;109(2):109-110. doi: 10.1016/j.bulcan.2021.11.012. Epub 2022 Jan 4.

Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30.

Bull Cancer. 2022 Feb;109(2):111-113. doi: 10.1016/j.bulcan.2021.09.021. Epub 2022 Jan 5.

[Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report].

Rinsho Shinkeigaku. 2020 Nov 27;60(11):768-772. doi: 10.5692/clinicalneurol.cn-001443. Epub 2020 Oct 27.

A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.

Eur J Cancer. 2020 Nov;139:169-172. doi: 10.1016/j.ejca.2020.08.005. Epub 2020 Sep 29.

[Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].

Rev Med Interne. 2020 Apr;41(4):284-288. doi: 10.1016/j.revmed.2019.12.023. Epub 2020 Jan 23.

Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinoma.

Future Oncol. 2024;20(28):2097-2107. doi: 10.1080/14796694.2024.2345043. Epub 2024 May 17.